44 results
8-K
EX-10.1
BTAX
Biostax Corp.
12 Oct 22
Entry into a Material Definitive Agreement
8:49am
package if the sublicense occurs before completing a clinical trial, 10% if the sublicence occurs after completing any trial, and 5% if sublicense
8-K
EX-10.1
id7moy ywd03di803vj
27 Jul 20
Departure of Directors or Certain Officers
3:07pm
8-K
EX-10.1
dfsa3e4
20 Mar 20
Immune Therapeutics, Inc. to Collaborate with Cytocom, Inc. to Develop Therapies for COVID-19
11:43am
8-K
EX-10.1
4hyv84g
25 Sep 19
Entry into a Material Definitive Agreement
5:05pm
8-K
gqrpyc58foq
25 Sep 19
Entry into a Material Definitive Agreement
5:05pm